1-Piperazinecarboxamide, N-[4-chloro-3-(trifluoromethyl)phenyl]-4-[6-[4-(4-methyl-1-piperazinyl)phenyl]thieno[2,3-d]pyrimidin-4-yl]-
- CAS No.
- 2756668-73-0
- Chemical Name:
- 1-Piperazinecarboxamide, N-[4-chloro-3-(trifluoromethyl)phenyl]-4-[6-[4-(4-methyl-1-piperazinyl)phenyl]thieno[2,3-d]pyrimidin-4-yl]-
- Synonyms
- VEGFR-3-IN-1;1-Piperazinecarboxamide, N-[4-chloro-3-(trifluoromethyl)phenyl]-4-[6-[4-(4-methyl-1-piperazinyl)phenyl]thieno[2,3-d]pyrimidin-4-yl]-
- CBNumber:
- CB713010194
- Molecular Formula:
- C29H29ClF3N7OS
- Molecular Weight:
- 616.1
- MDL Number:
- MOL File:
- 2756668-73-0.mol
1-Piperazinecarboxamide, N-[4-chloro-3-(trifluoromethyl)phenyl]-4-[6-[4-(4-methyl-1-piperazinyl)phenyl]thieno[2,3-d]pyrimidin-4-yl]- Chemical Properties,Uses,Production
Uses
VEGFR-3-IN-1 is a potent and selective VEGFR3 inhibitor with an IC50 of 110.4 nM. VEGFR-3-IN-1 significantly inhibits proliferation and migration of VEGF-C-induced human dermal lymphatic endothelial cells (HDLEC), MDA-MB-231, and MDA-MB-436 cells by inactivating the VEGFR3 signaling pathway, and also effectively inhibits breast cancer growth[1].
in vivo
VEGFR-3-IN-1 (50, 25 mg/kg; p.o.) reduces the tumor volume, and displays the strongest inhibitory activity in mice, with a growth inhibition rate of 61.9%[1]. VEGFR-3-IN-1 (10 mg/kg; p.o.) treatment shows the Cmax, AUC0-t , AUC0-∞ and t1/2 values of 420 ng/mL, 9219 ng h/mL, 12304 ng h/mL and 16 hours, respectively[1].
Animal Model: | Nude mice (carrying xenografted BC)[1] |
Dosage: | 50 mg/kg |
Administration: | P.o.;once |
Result: | Reduced the tumor volume, and displayed the strongest inhibitory activity in mice. |
Animal Model: | Sprague-Dawley (SD) rats [1] |
Dosage: | 10 mg/kg |
Administration: | P.o. (Pharmacokinetic Analysis) |
Result: | The Cmax, AUC0-t , AUC0-∞ and t1/2 were 420 ng/mL, 9219 ng h/mL, 12304 ng h/mL and 16 hours, respectively. |
IC 50
VEGFR3: 110.4 nM (IC50)
References
[1] Li Y, Yang G, et al. Discovery, Synthesis, and Evaluation of Highly Selective Vascular Endothelial Growth Factor Receptor 3 (VEGFR3) Inhibitor for the Potential Treatment of Metastatic Triple-Negative Breast Cancer. J Med Chem. 2021;64(16):12022-12048. DOI:10.1021/acs.jmedchem.1c00678
1-Piperazinecarboxamide, N-[4-chloro-3-(trifluoromethyl)phenyl]-4-[6-[4-(4-methyl-1-piperazinyl)phenyl]thieno[2,3-d]pyrimidin-4-yl]- Preparation Products And Raw materials
Raw materials
Preparation Products
1-Piperazinecarboxamide, N-[4-chloro-3-(trifluoromethyl)phenyl]-4-[6-[4-(4-methyl-1-piperazinyl)phenyl]thieno[2,3-d]pyrimidin-4-yl]- Suppliers
Supplier | Tel | Country | ProdList | Advantage | |
---|---|---|---|---|---|
Shanghai Yifei Biotechnology Co. , Ltd. | 021-65675885 18964387627 | customer_service@efebio.com | China | 11973 | 58 |
TargetMol Chemicals Inc. | 15002134094 | marketing@targetmol.cn | China | 19885 | 58 |
Sangon Biotech (Shanghai) Co.,Ltd. | 400-821-026 | Sales@sangon.com | China | 48813 | 58 |
Supplier | Advantage |
---|---|
Shanghai Yifei Biotechnology Co. , Ltd. | 58 |
TargetMol Chemicals Inc. | 58 |
Sangon Biotech (Shanghai) Co.,Ltd. | 58 |